The question remains: what will it take to prove that any protection device is having a meaningful impact on stroke risk?
A device designed to capture more TAVR procedural debris proves noninferior to an existing device in a large trial, but the ...
SILVER SPRING, MD — Unanimously disappointed with the end point used to determine clinical benefit, advisors to the US Food and Drug Administration (FDA) agreed the Sentinel Cerebral Protection System ...
In the first head-to-head comparison of two devices intended to protect against stroke in patients undergoing transcatheter ...
A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
A device designed to remove embolic material—fragments of tissue that can be released into the bloodstream during transcatheter aortic valve replacement (TAVR)—did not result in a reduction in the ...
TCT 319: Short -Term Clinical Effect of Cerebral Embolic Protection Device Following Transcatheter Aortic-Valve Replacement in Korea Population: The Sentinel Registry (Sentinel) Receive the the latest ...
Emboline's Emboliner system excels in a global trial, showing superior debris capture and procedural success in TAVR patients ...
Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...
CHICAGO -- Routine use of devices to prevent cerebral emboli during transcatheter aortic valve implantation (TAVI) did not prevent strokes, a large randomized trial showed. Incidence of stroke within ...
Emboline expects that its technology designed to reduce stroke risk during structural heart procedures will launch in the US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results